Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EU Backs Compulsory Licensing & Production Boost For COVID-19 Vaccines

IP Waiver Proposal Fails To Find Favor

Executive Summary

The European Commission is to present the World Health Organization with a set of proposals to tackle the barriers to the global rollout of COVID-19 vaccines. They include allowing the issue of compulsory licenses without consulting the rights holder, encouraging vaccine companies to expand production through licensing deals and contract manufacturing, and eliminating vaccine export restrictions.

You may also be interested in...



EU Reveals Plans For Unitary SPC & Review Of Compulsory Licensing

The EU has announced two separate legal initiatives, one that would improve IP protections, and another that could weaken them in the event of a future health crisis.

EU Reveals Plans For Unitary SPC & Review Of Compulsory Licensing

The EU has announced two separate legal initiatives, one that would improve IP protections, and another that could weaken them in the event of a future health crisis.

EU Ups The Ante On Opposition To COVID-19 IP Waiver

Leaked documents show that the European Commission has prepared a new proposal on compulsory licensing of coronavirus products to be tabled at the World Trade Organization’s Ministerial Conference next month.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS144350

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel